Company intelligence / Profile preview
Unity Biotechnology
South San Francisco, California, United Statesunitybiotechnology.com ↗
- Ownership
- Public · UBX
- Development stage
- Phase 2
01
Overview
Unity’s lead candidate UBX1325 has shown positive results in Phase 2 studies for DME. In the BEHOLD study, a single injection led to sustained statistically significant and clinically meaningful improvement in vision. The ASPIRE Phase 2b trial showed that UBX1325 achieved non-inferiority to aflibercept at most time points through 36 weeks, with durable visual acuity gains (+5.2 ETDRS letters at week 24; +5.5 at week 36). Safety profile remains favorable; full data expected Q2 2025.
- Therapeutic areas
- OphthalmologyImmunology
- Modalities
- small molecules (notably senolytic agents targeting cellular senescence)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $3.4M
- Total revenue
- $0
- Enterprise value
- $9.1M
Beyond the preview
Go deeper on Unity Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unity Biotechnology.